ASH 2022 | Novel ultra-sensitive MRD profiling tool predicts outcomes in DLBCL after frontline treatment
In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights findings from a study investigating the use of an ultra-sensitive blood-based tool to evaluate measurable residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL). Dr Westin explains how this novel tool uses a technology known as PhasED-Seq to truly identify patients who achieve undetectable MRD, and further highlights how this tool may be used to better predict patients at risk of relapse. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Consultancy, Research Funding; MorphoSys/Incyte Corporation: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Calithera: Consultancy, Research Funding; Iksuda: Consultancy; ADC Therapeutics: Consultancy, Research Funding; MonteRosa: Consultancy; AstraZeneca: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; Merck: Consultancy; Abbvie/GenMab: Consultancy; SeaGen: Consultancy.
